Abstracts tagged "Wegener’s granulomatosis"

Abstract Number: 3229 • 2015 ACR/ARHP Annual Meeting
Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility
Angel C.Y. Mak¹, Paul L.F. Tang², Gang Xie³, Pui-Yan Kwok², Paul A. Monach⁴, Simon Carette³, David Cuthbertson⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁶, Carol A. McAlear⁹, Larry W. Moreland¹⁰, Christian Pagnoux³, Philip Seo¹¹, Ulrich Specks¹², Antoine G. Sreih¹³, Steven R. Ytterberg¹⁴, Peter A. Merkel¹⁵, Katherine A. Siminovitch³, Sharon A. Chung¹⁶ and Vasculitis Clinical Research Consortium, ¹Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, ²Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Russell/Englemen Rheumatology Research Center, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Previous genome-wide association studies of granulomatosis with polyangiitis (Wegener’s, GPA) identified common genetic variants associated with susceptibility to GPA. However, since GPA is a…
Abstract Number: 853 • 2015 ACR/ARHP Annual Meeting
Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases
Antoine G. Sreih¹, Narender Annapureddy², Kevin Byram³, George Casey⁴, Vince Frangiosa⁵, Michael George⁶, Sapna Sangani⁷, Rebecca Sharim⁵ and Peter A. Merkel⁸, ¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ³Internal Medicine, Vanderbilt University, Nashville, TN, ⁴The Vasculitis Foundation, Kansas City, MO, ⁵Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁷Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: To facilitate clinical care and research, validated algorithms are needed to accurately identify patients with granulomatosis with polyangiitis (GPA; Wegener's). This study, sought to…
Abstract Number: 864 • 2015 ACR/ARHP Annual Meeting
Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis
Sarthak Gupta^1,2, Seema K. Patel², Mary Blake², Massimo G. Gadina², Wanxia L. Tsai², Simon Carette³, David Cuthbertson⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Larry W. Moreland⁹, Paul A. Monach¹⁰, Christian Pagnoux³, Philip Seo¹¹, Ulrich Specks¹², Antoine G. Sreih¹³, Steven R. Ytterberg¹⁴, Sarah K. Browne^1,15, Steven M. Holland¹, Mariana J. Kaplan², Peter A. Merkel¹⁶, Peter C. Grayson² and Vasculitis Clinical Research Consortium, ¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁵Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, ¹⁶Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anticytokine autoantibodies (ACAs) are pathogenic in many hematologic, pulmonary and infectious diseases. Evaluation in autoimmune diseases, including systemic lupus erythematosus (SLE), shows that ACAs…
Abstract Number: 870 • 2015 ACR/ARHP Annual Meeting
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Joanna Robson¹, Susan Ashdown², Jill Dawson³, Ebony Easley⁴, Don Gebhart⁵, Katherine Kellom⁶, Georgia Lanier⁷, Carol McAlear⁸, Nataliya Milman⁹, Jacqueline Peck¹⁰, Judy A. Shea¹¹, Gunnar Tomasson¹², Raashid Luqmani¹³, Peter F. Cronholm⁴ and Peter A. Merkel⁸, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²NONE, Banbury, United Kingdom, ³Nuffield Department of Population Health HSRU, University of Oxford, Oxford, United Kingdom, ⁴Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, ⁵NONE, Columbus, OH, ⁶PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, United Kingdom, ⁷NONE, Framingham, MA, ⁸Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹⁰NONE, Oxford, United Kingdom, ¹¹Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, United Kingdom, ¹²Rheumatology Section, Boston University, Boston, MA, ¹³Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's, (GPA), eosinophilic granulomatosis with polyangiitis (Churg-Strauss, EGPA), and microscopic polyangiitis (MPA),…
Abstract Number: 1861 • 2014 ACR/ARHP Annual Meeting
The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis
Antoine G. Sreih¹, Rana Ezzeddine², Juan Fan³, Lin Leng³, Simon Carette⁴, David Cuthbertson⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Carol A. Langford⁸, Carol McAlear⁹, Paul Monach¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³, Peter A. Merkel¹⁴ and Richard Bucala¹⁵, ¹Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Biostatistics, Bristol-Myers Squibb, Wallingford, CT, ³Yale University, New Haven, CT, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Department of Biostatistics, University of South Florida, Tampa, FL, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Rheum/Dept of Int Med, Yale University School of Med, New Haven, CT
Background/Purpose: Macrophage Migration Inhibitory Factor (MIF) is an immunoregulatory cytokine that may play a central role in the pathogenesis of granulomatous diseases. Two functional polymorphisms…
Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri¹, Natasha Dehghan², Eric C. Sayre³, Kamran Shojania¹ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA). We assessed…
Abstract Number: 1786 • 2014 ACR/ARHP Annual Meeting
Vasculitis As Underlying Cause of Death in the United States: 1999 – 2010
Alicia Rodriguez-Pla¹, Paul A. Monach² and Jose Rossello-Urgell³, ¹Rheumatology, Boston University, Boston, MA, ²Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA, ³Baylor Research Institut, Baylor Institute for Immunology Research, Dallas, TX
Background/Purpose Current data on mortality rates of primary vasculitis, which were tradionally associated with a dreadful prognosis, are limited. Therefore, we aimed to estimate the mortality rates…
Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Benjamin Terrier¹, Christian Pagnoux², Guillaume Geri³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaitre⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quemeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal⁷, Luc Mouthon⁷ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Internal Medicine, CHU, Clermont-Ferrand, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰University of Lyon, LYON, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Internal Medicine, CH, Valenciennes, France, ¹³Internal Medicine, Hôpital de Niort, Niort, France, ¹⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
Abstract Number: 1770 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study
Neda Amiri¹, Mohsen Sadatsafavi², Eric C. Sayre³, John M. Esdaile⁴ and J. Antonio Avina-Zubieta^2,5, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Chronic obstructive pulmonary disease (COPD) is increasingly recognized as an inflammatory condition. We aimed to identify the risk of newly recorded COPD among…
Abstract Number: 1767 • 2014 ACR/ARHP Annual Meeting
Granulomatosis with Polyangiitis (Wegener’s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome
Benjamin Terrier¹, Christophe Deligny², Xavier Puéchal³, Pascal Godmer⁴, Pierre Charles⁵, Gilles Hayem⁶, Bertrand Dunogué⁷, Pascal Cohen³, Serge Arfi⁸, Luc Mouthon³ and Loïc Guillevin for the French Vasculitis Study Group³, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Internal Medicine, CHU Fort de France, Fort de France, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ⁵Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁶Rhumatologie, Hopital Bichat, Paris Cedex 18, France, ⁷Internal Medicine, Hôpital Cochin, Paris, France, ⁸Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique
Background/Purpose Granulomatosis with polyangiitis (Wegener’s) (GPA) is an ANCA-associated vasculitis (AAV) predominantly affecting small-sized vessels, involving mainly the upper and lower respiratory tracts and kidneys.…
Abstract Number: 1758 • 2014 ACR/ARHP Annual Meeting
Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere
Lisa K. Stamp¹, Peter T. Chapman², Richard A. Watts³, Christopher Frampton¹ and John L. O'Donnell⁴, ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Rheumatology, Immunology & Allergy, Christchurch Hospital, Christchurch, New Zealand, ³Rheumatology Department Ipswich Hospital and University of East Anglia, Ipswich, United Kingdom, ⁴Rheumatology Immunology & Allergy, Canterbury Health Laboratories, Christchurch, New Zealand
Background/Purpose: GPA is a rare condition of unknown etiology. Prominent involvement of the upper and lower respiratory tracts suggests that inhaled antigens may trigger systemic…
Abstract Number: 1756 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases
James T. Rosenbaum¹, Dongseok Choi², Christine Harrington³, Patrick Stauffer⁴, David Wilson⁵, Seema Gupta⁴, Roger Dailey⁴, John Ng⁴, Eric Steele⁴, Patrick Yeatts⁶, Peter Dolman⁷, Valerie White⁷, Gerald Harris⁸, Craig Czyz⁹, Jill Foster⁹, Deepak Edward¹⁰, Hind Alkatan¹⁰, Bobby Korn¹¹, Don Kikkawa¹², Dinesh Selva¹³, Sander Dubovy¹⁴, Chris Alabiad¹⁵, David Tse¹⁵, Michael Kazim¹⁶, Payal Patel¹⁶ and Stephen R. Planck¹⁷, ¹OHSU, Portland, OR, ²Casey Eye Institute, Oregon Health and Science University, Portland, OR, ³Integrated Genomics, Oregon Health & Science University, Portland, OR, ⁴Oregon Health & Science University, Portland, OR, ⁵Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, ⁶Ophthalmology, Wake Forest University, Winston-Salem, NC, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Ohio State Univeristy, Columbus, OH, ¹⁰King Khaled Eye Hospital, Riyadh, Saudi Arabia, ¹¹University of California, San Diego, San Diego, CA, ¹²Ophthalmology, University of California, San Diego, San Diego, CA, ¹³Royal Adelaide Hospital, Adelaide, Australia, ¹⁴University of Miami, Miami, FL, ¹⁵Ophthalmology, University of Miami, Miami, FL, ¹⁶Columbia University, New York City, NY, ¹⁷Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR
Background/Purpose: Gene expression profiling provides diagnostic and therapeutic information in several malignancies, but its role in evaluating inflammatory disease is relatively untested. We hypothesized that…
Abstract Number: 1763 • 2014 ACR/ARHP Annual Meeting
Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis
Lucas Benarous¹, Benjamin Terrier², Bertrand Dunogué³, Pascal Cohen⁴, Xavier Puéchal⁴, Claire Le Jeunne⁴, Luc Mouthon⁴ and Loïc Guillevin for the French Vasculitis Study Group⁴, ¹Cochin Hospital, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ³Internal Medicine, Hôpital Cochin, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France
Background/Purpose Occupational and non-occupational exposures may play a role in the occurrence of ANCA-associated vasculitides (AAV) and affect their initial clinical-biological phenotype. Among these potential…
Abstract Number: 1236 • 2014 ACR/ARHP Annual Meeting
IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases
James T. Rosenbaum^1,2, Amanda Wong³, Patrick Stauffer³, Megan Troxell⁴, Donald Houghton⁵, Dongseok Choi⁶, Christine Harrington⁷, David Wilson⁸, Hans Grossniklaus⁹, Roger Dailey³, John Ng³, Eric Steele³, Patrick Yeatts¹⁰, Peter Dolman¹¹, Valerie White¹¹, Craig Czyz¹², Jill Foster¹², Deepak Edward¹³, Hind Alkatan¹³, Don Kikkawa¹⁴, Bobby Korn¹⁵, Dinesh Selva¹⁶, Gerald Harris¹⁷, Michael Kazim¹⁸, Payal Patel¹⁸ and Stephen R. Planck¹⁹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Pathology, Oregon Health and Science University, Portland, OR, ⁵Pathology, Oregon Health & Science University, Portland, OR, ⁶Casey Eye Institute, Oregon Health and Science University, Portland, OR, ⁷Integrated Genomics, Oregon Health & Science University, Portland, OR, ⁸Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, ⁹Ophthalmology, Emory University, Atlanta, GA, ¹⁰Ophthalmology, Wake Forest University, Winston-Salem, NC, ¹¹University of British Columbia, Vancouver, BC, Canada, ¹²Ohio State Univeristy, Columbus, OH, ¹³King Khaled Eye Hospital, Riyadh, Saudi Arabia, ¹⁴Ophthalmology, University of California, San Diego, San Diego, CA, ¹⁵University of California, San Diego, San Diego, CA, ¹⁶Royal Adelaide Hospital, Adelaide, Australia, ¹⁷Medical College of Wisconsin, Milwaukee, WI, ¹⁸Columbia University, New York City, NY, ¹⁹Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR
Background/Purpose: IgG4-related disease is an emerging clinical entity which frequently involves tissue within the orbit. In order to appreciate the implications of IgG4 immunostaining, we…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].